High-dose selenium for critically ill patients with systemic inflammation: pharmacokinetics and pharmacodynamics of selenious acid: a pilot study
- PMID: 20080034
- DOI: 10.1016/j.nut.2009.06.022
High-dose selenium for critically ill patients with systemic inflammation: pharmacokinetics and pharmacodynamics of selenious acid: a pilot study
Abstract
Objective: Systemic inflammatory response syndrome is characterized by increased urinary excretion of selenium and low serum concentration. Repletion by parenteral selenite is the most efficacious form of supplementation. However, the optimum safe dose and mode of administration remain controversial. We aimed to determine pharmacokinetic and pharmacodynamic profiles of selenite and estimate a safe dose to optimize selenium status.
Methods: A prospective, randomized, pilot study in 20 patients with systemic inflammatory response syndrome compared a high-dose (HD) group that received a loading dose of selenium as selenite 15.18 micromol over 2 h and thereafter 10.12 micromol/d as a continuous intravenous infusion (CIV) for 10 d with a very-high-dose (VHD) group that received a loading dose of 25.30 micromol over 2 h and thereafter 20.24 micromol as a CIV for 10 d. Clinical outcome was evaluated by length of stay in the intensive care unit, incidence of ventilator-associated pneumonia, and Sequential Organ Failure Assessment score.
Results: Patients in group HD (n = 10, age 54 +/- 23 y) had an Acute Physiology and Chronic Health Evaluation II score of 23 +/- 5 and a Sequential Organ Function Assessment score of 10 +/- 2. Those in group VHD (n = 10, age 41 +/- 19 y) had scores of 21 +/- 7 and 8 +/- 3, respectively. Pharmacokinetic concentration/time curves for serum selenium overlapped but were independent of dose, whereas the pharmacodynamics were different, showing maximum glutathione peroxidase activity only with VHD. Glutathione peroxidase decreased after day 7 independently of the selenium dose. Clinical outcomes were similar in both groups.
Conclusion: A bolus loading dose of selenite providing 2000 microg of selenium (25.30 micromol) followed by a CIV of 1600 microg/d (20.24 micromol/d) for 10 d is most effective at returning serum selenium to physiologic levels and safely maximizing glutathione peroxidase activity.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Selenium supplementation in the critically ill: posology and pharmacokinetics.Curr Opin Clin Nutr Metab Care. 2009 May;12(3):273-80. doi: 10.1097/MCO.0b013e32832a0cc2. Curr Opin Clin Nutr Metab Care. 2009. PMID: 19333120 Review.
-
Effect of selenium supplementation on biochemical markers and outcome in critically ill patients.Clin Nutr. 2007 Feb;26(1):41-50. doi: 10.1016/j.clnu.2006.10.003. Epub 2006 Dec 14. Clin Nutr. 2007. PMID: 17174015 Clinical Trial.
-
[Pharmaconutrition with parenteral selenium in sepsis].Med Intensiva. 2014 Apr;38(3):173-80. doi: 10.1016/j.medin.2013.07.007. Epub 2013 Sep 8. Med Intensiva. 2014. PMID: 24021703 Review. Spanish.
-
Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome.Crit Care Med. 1999 Sep;27(9):1807-13. doi: 10.1097/00003246-199909000-00017. Crit Care Med. 1999. PMID: 10507602 Clinical Trial.
-
Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.Crit Care Med. 2007 Jan;35(1):118-26. doi: 10.1097/01.CCM.0000251124.83436.0E. Crit Care Med. 2007. PMID: 17095947 Clinical Trial.
Cited by
-
Improving the Practice of Nutrition Therapy in the NRITLD Critically Ill Patients: An International Quality Improvement Project.Tanaffos. 2011;10(4):31-7. Tanaffos. 2011. PMID: 25191385 Free PMC article.
-
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.J Gynecol Oncol. 2021 Sep;32(5):e73. doi: 10.3802/jgo.2021.32.e73. Epub 2021 Jun 1. J Gynecol Oncol. 2021. PMID: 34132071 Free PMC article.
-
A general covalent binding model between cytotoxic selenocompounds and albumin revealed by mass spectrometry and X-ray absorption spectroscopy.Sci Rep. 2020 Jan 27;10(1):1274. doi: 10.1038/s41598-020-57983-y. Sci Rep. 2020. PMID: 31988319 Free PMC article.
-
Pharmaconutrition revisited for critically ill patients with coronavirus disease 2019 (COVID-19): Does selenium have a place?Nutrition. 2021 Jan;81:110989. doi: 10.1016/j.nut.2020.110989. Epub 2020 Aug 31. Nutrition. 2021. PMID: 33049573 Free PMC article.
-
Antioxidants and micronutrient supplementation in trauma patients.Curr Opin Clin Nutr Metab Care. 2012 Mar;15(2):181-7. doi: 10.1097/MCO.0b013e32835076df. Curr Opin Clin Nutr Metab Care. 2012. PMID: 22261953 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical